Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/16/2008
 
First Published:
3/22/2007
1.
Phase III Randomized Study of PR1 Leukemia Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Acute Myeloid Leukemia in Remission
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
VACCINE-PR1-104
UCCRC-14613B, NCT00454168
2.
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R)]
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Other
2006-0360
NCT00415857
Last Modified:
4/25/2008
 
First Published:
7/6/2007
3.
Phase II Study of WT1 and PR1 Peptide Vaccines and Sargramostim (GM-CSF) in Patients With Low-Risk Myeloid Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 85
NHLBI
NHLBI-07-H-0159
07-H-0159, NCT00499772
Last Modified:
10/2/2007
 
First Published:
7/24/2007
4.
Phase II Study of PR1 Leukemia Peptide Vaccine Formulated in Incomplete Freund's Adjuvant Followed By Sargramostim (GM-CSF) in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
VACCINE-PR1-204
PR1-204, NCT00513578
5.
Vaccination for Patients With High Risk Cancers of the Blood
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 85
NHLBI
070091
07-H-0091, NCT00433745
6.
Safety of Peptide Vaccination for Patients with Myelodysplastic Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 to 85
NHLBI
060062
06-H-0062, NCT00270452
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute